| Literature DB >> 32213710 |
Yao Meng1, Jun Li1, Zhizhong Ye2, Zhihua Yin2, Qing Sun1, Zhuojun Liao1, Guanhua Li1, Jun Deng1, Lu Liu3, Yuqing Yu1, Li Wu4, Haibo Zhou1,2, Nan Shen1,2,5,6,7.
Abstract
Monocyte-derived DCs (moDCs) have been implicated in the pathogenesis of autoimmunity, but the molecular pathways determining the differentiation potential of these cells remain unclear. Here, we report that microRNA-148a (miR-148a) serves as a critical regulator for moDC differentiation. First, miR-148a deficiency impaired the moDC development in vitro and in vivo. A mechanism study showed that MAFB, a transcription factor that hampers moDC differentiation, was a direct target of miR-148a. In addition, a promoter study identified that miR-148a could be transcriptionally induced by PU.1, which is crucial for moDC generation. miR-148a ablation eliminated the inhibition of PU.1 on MAFB. Furthermore, we found that miR-148a increased in monocytes from patients with psoriasis, and miR-148a deficiency or intradermal injection of antagomir-148a immensely alleviated the development of psoriasis-like symptoms in a psoriasis-like mouse model. Therefore, these results identify a pivotal role for the PU.1-miR-148a-MAFB circuit in moDC differentiation and suggest a potential therapeutic avenue for autoimmunity.Entities:
Keywords: Autoimmune diseases; Autoimmunity; Dendritic cells; Dermatology
Mesh:
Substances:
Year: 2020 PMID: 32213710 PMCID: PMC7205423 DOI: 10.1172/jci.insight.133721
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708